BrainEx Now Tests Drugs in Donated Human Brains—Without Reviving a Person

BrainEx has progressed from an isolated pig-brain experiment to research using whole human brains donated after death. A 2026 Science report indexed by PubMed describes Bexorg restoring selected functions in brains from deceased donors to test drugs for neurodegenerative diseases—not reviving a person or recovering consciousness.

The important change is the availability of a more anatomically complete human-tissue model for preclinical research. What remains true is the central limit of the original work: circulation, metabolism and cellular responses can occur without the coordinated brain activity associated with awareness, memory or thought.

What the original BrainEx experiment restored

BrainEx began as an extracorporeal perfusion system developed by a Yale-led research team. In the Nature study published on April 17, 2019, the researchers connected isolated pig brains to the system four hours after death and circulated an oxygen-carrying, cell-free solution through their blood vessels under near-normal temperature conditions.

The treatment restored microcirculation and active metabolism while preserving aspects of tissue structure. The researchers also observed vascular responses, inflammatory responses from glial cells and spontaneous activity at individual synapses, alongside less cell death than in control brains.

These findings challenged the assumption that the loss of circulation makes every process in a large mammalian brain immediately and uniformly irreversible. They did not show that the brain had resumed integrated operation: the experiment detected no global electrocorticographic activity, the large-scale electrical pattern that would have indicated coordinated whole-brain function.

Why signs of life do not amount to resurrection

Biologically active cells are not equivalent to a living, conscious individual. A cell can consume oxygen, metabolize nutrients, react to a chemical stimulus or release a signalling molecule without participating in the organized network activity needed for perception and awareness.

BrainEx therefore occupies a different category from clinical resuscitation. A patient receiving cardiopulmonary resuscitation has a brain that remains inside the body and connected to the senses, spinal cord, immune system and other organs. BrainEx operates on an isolated organ after death and is intended to preserve experimentally useful tissue functions.

The absence of global electrical activity in the pig study is strong evidence that consciousness was not restored under that protocol. It is not proof that every conceivable future perfusion method would be incapable of producing more extensive neural activity, which is why electrical monitoring and predefined safeguards remain ethically important.

The human-brain platform changes what researchers can measure

On its current technology page, Bexorg describes BrainEx as a platform that perfuses drugs, biologics and gene therapies through intact postmortem human brains and measures their movement and molecular effects in real time. The same page identifies the brains as specifically authorized postmortem donations, separate from ordinary organ-donor registration, and characterizes them as incapable of regaining consciousness or awareness.

An intact human brain retains regional anatomy, mature cell populations, blood vessels and disease-related tissue changes that cannot all be reproduced together in a culture dish. Researchers can examine whether a compound reaches a target region, engages an intended molecule or produces a measurable cellular response while the organ’s vascular pathways remain available.

That makes the model potentially valuable between conventional laboratory experiments and studies in living volunteers. Animal models may not reproduce human disease biology, while isolated cells and tissue slices remove much of the organ’s spatial and vascular context. A perfused postmortem brain can preserve more of that context without exposing a living participant to an experimental therapy.

The model nevertheless cannot determine whether a treatment improves memory, movement, mood, daily functioning or survival. It also lacks normal communication with the rest of the body, including immune, endocrine and metabolic processes that can change a drug’s effects. Its ability to predict clinical outcomes will require validation against evidence from living patients rather than assumption from cellular responses alone.

Consent and consciousness remain separate ethical questions

Specific consent matters because whole-brain perfusion is not interchangeable with routine tissue donation. Authorization must cover research involving the intact brain, while organ recovery for lifesaving transplantation takes priority. Once removed, the research brain is no longer connected to the donor’s body, sensory organs or peripheral nerves.

Consciousness presents a different problem. Consent determines whether the tissue may be used; it does not by itself resolve what investigators should do if a future system produces unexpected coordinated activity. Protocols therefore need clear monitoring thresholds and rules for suppressing or terminating activity before an experiment begins.

Claims about an inability to regain awareness also need to remain tied to the actual system being used. The available evidence supports the narrower conclusion that reported BrainEx experiments have maintained selected cellular and molecular functions without restoring organized whole-brain activity. It does not establish a universal limit for all future technologies.

What BrainEx has—and has not—changed

BrainEx has expanded the period and conditions under which scientists can obtain dynamic measurements from postmortem brain tissue. Its transition to donated human brains adds a research environment for studying drug distribution, target engagement, disease biology and molecular biomarkers in an organ that retains much of its physical structure.

It has not produced a conscious isolated brain, reversed a declaration of death or returned an animal or human being to life. Nor is the platform itself an approved treatment for cardiac arrest, stroke, Alzheimer’s disease, Parkinson’s disease or another neurological disorder.

The accurate interpretation is consequential without being cinematic: death of the individual does not mean every brain cell instantly loses all capacity to function. BrainEx uses that remaining biological capacity to create a responsive research model, while the defining features of a living person—integrated physiology and consciousness—remain absent.

Also read:

• Startups Are Reviving Dead Brains — And Big Pharma Can’t Look Away
• Can I Really Get Through Life Without Technology?
• ChatGPT Outperforms Human Doctors At Accurately Diagnosing Patients